

PRECEPTORSHIP PROGRAMME

Gastrointestinal Tumours

Multidisciplinary management,
standards of care and future perspectives

SINGAPORE

14-16 NOVEMBER 2017

Co-Chairs Andrés Cervantes, ES
 Su Pin Choo, SG

ESMO PRECEPTORSHIP PROGRAMME GASTROINTESTINAL TUMOURS

Multidisciplinary management, standards of care and future perspectives

Singapore
14-16 November 2017

CO-CHAIRS:

Andrés Cervantes, Spain
Su Pin Choo, Singapore

SPEAKERS:

Chung Yip Chan, Singapore	Sun Young Rha, South Korea
Ian Chau, United Kingdom	Elizabeth Smyth, United Kingdom
Min Hoe Chew, Singapore	Jimmy Bok-Yan So, Singapore
Dawn Qingqing Chong, Singapore	Sho Suzuki, Japan
Clarinda Wei Ling Chua, Singapore	Iain Bee Huat Tan, Singapore
Chiun Hsu, Taiwan	Patrick Tan, Singapore
Tony Lim Kiat Hon, Singapore	Melissa Teo Ching Ching, Singapore
Brigette Buig Yue Ma, Hong Kong	Wei Peng Yong, Singapore

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, in special situations and side effects of treatments
- To learn about the management of unresectable/relapsing Hepatocellular Carcinoma and new approaches after failure of 1st line treatment
- To review the standard of care of anal carcinomas
- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment in gastric cancer
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **17 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Tuesday, 14 November 2017

09:00-09:15 15'	Welcome and introduction	Andrés Cervantes, ES Su Pin Choo, SG
09:15-10:55 100'	SESSION 1 Early colorectal cancer	Chair: Ian Chau, UK
40'	What pathology can tell us in the approach of localized colorectal cancer (including microsatellite instability and molecular aspects)	Tony Lim Kiat Hon, SG
20'	State-of-the-art: Standard of surgical practice for resectable rectal cancer	Min Hoe Chew, SG
20'	State-of-the-art: Standard of radio/chemotherapy for rectal cancer	Ian Chau, UK
20'	The role of adjuvant chemotherapy in localized rectal cancer	Andrés Cervantes, ES
10:55-11:15	Coffee break	
11:15-12:45 90'	SESSION 2 Adjuvant settings of colorectal cancer	Chair: Andrés Cervantes, ES
30'	Adjuvant treatment for colon cancer III	Andrés Cervantes, ES
30'	Adjuvant treatment of stage II: Which patients to treat?	Dawn Qingqing Chong, SG
3x10'	3 x Participants clinical case discussion	Faculty
12:45-14:00	Lunch	
14:00-16:00 120'	SESSION 3 Metastatic colorectal cancer, liver limited metastases	Chair: Chung Yip Chan, SG
30'	Review of the ESMO consensus conference on metastatic colorectal cancer	Andrés Cervantes, ES
30'	Resection of liver limited metastases (resectable cases) <ul style="list-style-type: none"> - Upfront - After neo-adjuvant treatment - Repeated hepatectomy 	Chung Yip Chan, SG
30'	Unresectable or borderline resectable chemotherapy +/- targeted agents	Iain Bee Huat Tan, SG
3x10'	3 x Co-chairs clinical case discussion	Faculty
16:00-16:30	Coffee break	
16:30-17:30 60'	SESSION 4 Special clinical situations: Mono- or oligometastatic disease	Chair: Andrés Cervantes, ES
30'	Treatment of metastatic disease confined to the peritoneum <ul style="list-style-type: none"> - Resection - HIPEC - PIPEC 	Melissa Teo Ching Ching, SG
30'	Options of locoregional treatment of liver metastases <ul style="list-style-type: none"> - Intra-arterial therapy - Chemo-embolisation - SIRT - Local radiation 	Andrés Cervantes, ES

Wednesday, 15 November 2017

08:30-09:45 75'	SESSION 5 Metastatic colorectal cancer I	Chair: Brigette Buig Yue Ma, HK
50'	Chemotherapy and targeted agents in 1 st line	Brigette Buig Yue Ma, HK
25'	The role of maintenance, appropriate endpoints according to ESMO consensus	Andrés Cervantes, ES
09:45-10:45 60'	SESSION 6 Metastatic colorectal cancer II	Chair: Brigette Buig Yue Ma, HK
30'	What to do after 1 st line failure	Clarinda Wei Ling Chua, SG
30'	Management of treatment-related side effects <ul style="list-style-type: none"> - GI-Toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome 	Andrés Cervantes, ES
10:45-11:15	Coffee break	
11:15-12:25 70'	SESSION 7 Hepatocellular Carcinoma (HCC)	Chair: Su Pin Choo, SG
20'	1 st line treatment for unresectable HCC	Chiun Hsu, TW
20'	Treatment for HCC after 1 st line progression	Su Pin Choo, SG
3x10'	3 x Participants clinical case discussion	Faculty
12:25-12:55 30'	SESSION 8 Anal tumours	Chair: Su Pin Choo, SG
30'	Standard of care for anal squamous carcinomas	Ian Chau, UK
12:55-14:00	Lunch	
14:00-15:20 80'	SESSION 9 Epidemiology, pathology and endoscopy of gastric cancer	Chair: Ian Chau, UK
20'	Epidemiology (including GE junction) and clinical presentation	Wei Peng Yong, SG
30'	Endoscopy in gastric cancer: New imaging techniques, new treatment modalities (EMR, ESD)	Sho Suzuki, JP
30'	Surgery for gastric and GE junction cancer, primary, palliative - where and when?	Jimmy Bok-Yan So, SG
15:20-15:50	Coffee break	
15:50-17:00 70'	SESSION 10 Surgical, adjuvant and neoadjuvant treatment of gastric cancer	Chair: Sun Young Rha, KR
40'	Neo- and adjuvant treatment for gastric cancer and GE junction cancer	Ian Chau, UK
30'	Chemotherapy for metastatic disease	Sun Young Rha, KR
20:00	Dinner	

Thursday, 16 November 2017

08:30-09:30 60'	SESSION 11 Clinical discussions	Chair: Andrés Cervantes, ES
50'	Molecular classification in gastric cancer and GE junction cancer	Patrick Tan, SG
10'	Discussion	Faculty
09:30-10:00	Coffee break	
10:00-12:10 150'	SESSION 12 Advanced disease	Chair: Elizabeth Smyth, UK
40'	Biological targeted agents (including HER2, EGFR, angiogenesis)	Elizabeth Smyth, UK
40'	New targets (including cMET, FGF, mTOR, PDL,...)	Sun Young Rha, KR
5x10'	5 x Participants clinical case discussion	Faculty
12:10-12:20 10'	Conclusion and farewell	Andrés Cervantes, ES Su Pin Choo, SG
12:20-13:20	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org

